Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

AIV007

Small molecule

AAiViva BioPharma, Inc.

0

Indications

3

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Neovascular (wet) Age-Related Macular Degeneration

NCT07557121

Clinical

Trials by Indication[1]

Age-Related Macular Degeneration1 trial

Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration

Completed·AAiViva BioPharma, Inc.·Phase 1·NCT04422899·3 enrolled

Neovascular Age-related Macular Degeneration1 trial

A Phase 1 Study of the Safety, Pharmacokinetics, and Exploratory Efficacy of Periocular Administration of AIV007 in Subjects With Macular Edema Secondary to Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

Completed·AAiViva BioPharma, Inc.·Phase 1·NCT05698329·19 enrolled

Neovascular (Wet) Age-Related Macular Degeneration1 trial

A Phase 2, Multicenter, Randomized, Active-controlled Trial of the Safety and Efficacy of AIV007 by Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration

Recruiting·AAiViva BioPharma, Inc.·Phase 2·NCT07557121·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for AIV007. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AIV007 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
SEC EDGAR — AiViva BioPharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: AAiViva BioPharma, Inc.

Related News